Cargando…

Screening of key genes associated with R-CHOP immunochemotherapy and construction of a prognostic risk model in diffuse large B-cell lymphoma

Diffuse large B-cell lymphoma (DLBCL) is a common subtype of non-Hodgkin lymphoma, which is curable in the majority of patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) immunochemotherapy. However, the therapeutic mechanism of R-CHOP has not been...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Ran, Chen, Zhi, Wang, Shujun, Zhao, Gang, Gu, Yan, Han, Qi, Chen, Baoan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2019
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6755150/ https://www.ncbi.nlm.nih.gov/pubmed/31485671 http://dx.doi.org/10.3892/mmr.2019.10627

Ejemplares similares

Anemia as a useful biomarker in patients with diffuse large B-cell lymphoma treated with R-CHOP immunochemotherapy
por: Hong, Junshik, et al.
Publicado: (2014)

The Prognostic Impact of Comorbidities in Patients with De-Novo Diffuse Large B-Cell Lymphoma Treated with R-CHOP Immunochemotherapy in Curative Intent
por: Kocher, Florian, et al.
Publicado: (2020)

An integrated prognostic model for diffuse large B‐cell lymphoma treated with immunochemotherapy
por: Rodríguez, Marta, et al.
Publicado: (2022)

Body Composition as a Predictor of Toxicity and Prognosis in Patients with Diffuse Large B-Cell Lymphoma Receiving R-CHOP Immunochemotherapy
por: Guo, Jiaxun, et al.
Publicado: (2021)

A modified prognostic model in patients with diffuse large B-cell lymphoma treated with immunochemotherapy
por: Zhao, Peiqi, et al.
Publicado: (2021)

Prognostic significance of BLK expression in R-CHOP treated diffuse large B-cell lymphoma
por: Choi, Soyeon, et al.
Publicado: (2022)

Consolidative Radiotherapy after Complete Remission following R-CHOP Immunochemotherapy in Stage III–IV Diffuse Large B-Cell Lymphoma Patients: A Systematic Review and Meta-Analysis
por: Choi, Kyu-Hye, et al.
Publicado: (2023)

Clinical Response to CHOP vs. R-CHOP in Adult Patients with Diffuse Large B-Cell Lymphomas
por: Tariq, Ayesha, et al.
Publicado: (2018)

Impact of relative dose intensity (RDI) in CHOP combined with rituximab (R-CHOP) on survival in diffuse large B-cell lymphoma
por: Terada, Yoshiki, et al.
Publicado: (2009)

P1189: ENDOTHELIAL ACTIVATION AND STRESS INDEX IS AN INDEPENDENT PROGNOSTIC FACTOR OF DIFFUSE LARGE B-CELL LYMPHOMA TREATED WITH STANDARD IMMUNOCHEMOTHERAPY
por: Thanhakun, Ronakrit, et al.
Publicado: (2023)

Construction and Validation of a Novel Nomogram for Predicting the Recurrence of Diffuse Large B Cell Lymphoma Treated with R-CHOP
por: Gong, Yuxi, et al.
Publicado: (2023)

The Prognostic Impact of Dose-attenuated R-CHOP Therapy for Elderly Patients with Diffuse Large B-cell Lymphoma
por: Tanimura, Akira, et al.
Publicado: (2018)

Prognostic nutritional index and the prognosis of diffuse large b-cell lymphoma: a meta-analysis
por: Luan, Chunyan, et al.
Publicado: (2020)

The Geriatric Prognostic Index: a clinical prediction model for survival of older diffuse large B-cell lymphoma patients treated with standard immunochemotherapy
por: Isaksen, Kathrine T., et al.
Publicado: (2023)

Sciatic diffuse large B-cell lymphoma with treatment response to CHOP and radiotherapy
por: Shomal Zadeh, Firoozeh, et al.
Publicado: (2023)

A study on the prevention of hemorrhage and perforation in patients with primary gastric diffuse large‐B cell lymphoma during treatment with immunochemotherapy
por: Zhang, Limei, et al.
Publicado: (2023)

Clinical Analysis of the HBV Infection Status of 135 Patients with Diffuse Large B Cell Lymphoma Treated with R-CHOP or CHOP/CHOP-Like Chemotherapy
por: Guo, Wei, et al.
Publicado: (2015)

Association of Occupational Pesticide Exposure With Immunochemotherapy Response and Survival Among Patients With Diffuse Large B-Cell Lymphoma
por: Lamure, Sylvain, et al.
Publicado: (2019)

The impact of sMICA/sMICB on immunochemotherapy outcomes in newly diagnosed diffuse large B-cell lymphoma
por: Yoon, Sang Eun, et al.
Publicado: (2023)

Emerging Role of Consolidative Radiotherapy After Complete Remission Following R-CHOP Immunochemotherapy in Stage III–IV Diffuse Large B-Cell Lymphoma: A Single Institutional and Case-Matched Control Study
por: Hong, Ji Hyun, et al.
Publicado: (2021)

The Modified Glasgow Prognostic Scores as a Predictor in Diffuse Large B Cell Lymphoma Treated with R-CHOP Regimen
por: Kim, Yundeok, et al.
Publicado: (2014)

A prognostic model based on gene expression parameters predicts a better response to bortezomib-containing immunochemotherapy in diffuse large B-cell lymphoma
por: Mosquera Orgueira, Adrián, et al.
Publicado: (2023)

GM-CSF enhanced the effect of CHOP and R-CHOP on inhibiting diffuse large B-cell lymphoma progression via influencing the macrophage polarization
por: Zhang, Yu, et al.
Publicado: (2021)

RAC1, a Potential Diagnostic and Prognostic Marker for Diffuse Large B Cell Lymphoma
por: Wu, Xue, et al.
Publicado: (2022)

Screening of Adverse Prognostic Factors and Construction of Prognostic Index in Previously Untreated Concurrent Follicular Lymphoma and Diffuse Large B-Cell Lymphoma
por: Qu, Zhenjie, et al.
Publicado: (2022)

Prognosis of patients with diffuse large B cell lymphoma not reaching complete response or relapsing after frontline chemotherapy or immunochemotherapy
por: Rovira, Jordina, et al.
Publicado: (2014)

Efficacy of rituximab combined with CHOP for treating patients with diffuse large B-cell lymphoma
por: Hu, Xin, et al.
Publicado: (2017)

R-CHOP resistance in diffuse large B-cell lymphoma: biological and molecular mechanisms
por: Wang, Liang, et al.
Publicado: (2021)

Prognostic value of BCL2 and TP53 genetic alterations for diffuse large B-cell lymphoma patients treated with R-CHOP
por: Qin, Yan, et al.
Publicado: (2022)

Evaluation of 4 prognostic indices in follicular lymphoma treated in first line with immunochemotherapy
por: Rodríguez-Sevilla, Juan Jose, et al.
Publicado: (2022)

Outcome of R-CHOP or CHOP Regimen for Germinal Center and Nongerminal Center Subtypes of Diffuse Large B-Cell Lymphoma of Chinese Patients
por: Huang, Ying, et al.
Publicado: (2012)

ROBUST: Lenalidomide-R-CHOP versus placebo-R-CHOP in previously untreated ABC-type diffuse large B-cell lymphoma
por: Nowakowski, Grzegorz S, et al.
Publicado: (2016)

TP53 Arg72 as a favorable prognostic factor for Chinese diffuse large B-cell lymphoma patients treated with CHOP
por: Liu, Yalu, et al.
Publicado: (2017)

Association of progression-free or event-free survival with overall survival in diffuse large B-cell lymphoma after immunochemotherapy: a systematic review
por: Zhu, Jie, et al.
Publicado: (2020)

P1216: ZANUBRUTINIB PLUS R-CHOP(RI-CHOP) AS THE TREATMENT FOR DOUBLE EXPRESSION OF MYC/BCL2 IN PATIENTS WITH DIFFUSED LARGE B-CELL LYMPHOMA
por: Ren, K., et al.
Publicado: (2022)

Expression IRF/MUM1>25% Predictor to Three-year Survival of Diffuse Large B Cell Lymphoma in the Immunochemotherapy Era
por: Sofo-Hafizovic, Alma, et al.
Publicado: (2016)

R-CHOP chemoimmunotherapy followed by autologous transplantation for the treatment of diffuse large B-cell lymphoma
por: Lee, Hong Ghi, et al.
Publicado: (2014)

Complications and outcomes in diffuse large B‐cell lymphoma with gastric lesions treated with R‐CHOP
por: Kadota, Tomohiro, et al.
Publicado: (2019)

Safety and efficacy of atezolizumab with rituximab and CHOP in previously untreated diffuse large B-cell lymphoma
por: Younes, Anas, et al.
Publicado: (2022)

Differential Impact of Relative Dose-Intensity Reductions in Diffuse Large B-Cell Lymphoma Treated with R-CHOP21 or R-CHOP14
por: Gutiérrez, Antonio, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_f986bu3lumuj2pd117l1gilpf4